Latest research on anti-RSV

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

Latest findings

24 h later, monolayers were washed and incubated with peroxidase-conjugated goat anti-RSV antibody (Biogenesis). [source, 2000]
2 wk after final vaccination, the geometric mean endpoint anti-RSV G protein IgG antibody titers of mice vaccinated with peptide 19– KLH or peptide 22–KLH were 1517 and 5611, respectively. [source, 1998]
Immune sera were analyzed for anti-RSV F antibody titers (IgG, IgG1, and IgG2a, respectively) using ELISAs and for RSV-specific plaque reduction titers. [source, 1998]